§Concluded several BD deals & agreements that have enhanced the Ipsen R&D pipeline and commercial portfolio
CEO Pharma, Pierre Fabre Group (2000-2002)
§Responsible for Primary Care, Oncology, OTC and Odontological business with a worldwide turnover of €610mm and 3,700 staf
§Participated in the merger with bioMérieux
VP Finance & IT, Novartis (1997-2000)